Servier, an independent international pharmaceutical group, is announcing that it has successfully made an inaugural private placement for 405 million dollars on the US private placement (USPP) market, in four tranches with maturities of 7, 10, 12, and 15 years.
This first Servier private placement was enthusiastically welcomed by American investors and was very widely oversubscribed by more than four times, with a particularly long maturity of 12 and 15 years, highlighting the Group’s appeal and American investors’ confidence in the Group’s strategy, notably in the US.
This USPP is part of the refinancing of the syndicated loan set up in August 2018 for the acquisition of Shire’s oncology branch. This operation has enabled Servier to support its growth on the American market, where the Group is present through Servier Pharmaceuticals, its commercial subsidiary, and Servier BioInnovation.
“This first transaction on the US private placement market confirms investors’ confidence in Servier’s strategy and provides the Group with long-term foundations for financing in line with its development ambitions,”
confirms Dominique Brissy, Senior Executive Vice-President Finance and Information Systems.
This first USPP enables the Group to diversify its sources of funding and to lengthen the average debt maturity.
Moving forward, Servier intends to make further use of this type of financing, enabling it to welcome on board long-term investors to support its business growth in France and around the world.
For this private placement, the Servier Group was supported by Société Générale.